Results 61 to 70 of about 75,684 (261)

Open and Arthroscopic Acetabular Labral Reconstructions Are Associated With Improvements in Hip Patient‐Reported Outcome Measures at 1 Year, but Only an Open Approach Is Associated With Significant Reductions in Pain

open access: yesArthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To compare initial outcomes for open versus arthroscopic acetabular labral reconstruction (ALR) using fresh meniscus allograft transplantation. Methods With informed consent, patients scheduled to undergo ALR were enrolled into a registry.
John R. Baumann   +5 more
wiley   +1 more source

Non‐melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin‐6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study

open access: yesArthritis &Rheumatology, Accepted Article.
Background Non‐melanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with Janus kinase inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Method This study used data from the British Society for Rheumatology Rheumatoid Arthritis Register (BSRBR‐RA) linked
Zixing Tian   +8 more
wiley   +1 more source

The role of feed-in tariffs in encouraging insurance companies to invest in renewables [PDF]

open access: yesInsurance Markets and Companies
In an environment where public funding is insufficient to meet international climate and energy goals, feed-in tariffs serve as an essential mechanism to mitigate investment risk and foster the participation of insurance companies as institutional ...
Serhiy Lyeonov   +6 more
doaj   +1 more source

Performance evaluation and analysis of Chinese insurance companies under uncertain financial markets. [PDF]

open access: yesHeliyon, 2023
Jia-Ying J   +5 more
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease   +20 more
wiley   +1 more source

Prevalence of Phelan McDermid Syndrome Estimated To Be ~1:7300 Using a Multisource Model

open access: yesAutism Research, EarlyView.
ABSTRACT Estimating the prevalence of genetic disorders is complicated by many factors including sampling bias and differing methods of estimation. However, establishing the true prevalence of these disorders is critical for understanding disease burden, pharmacoeconomic modeling, and resource allocation for testing and care.
Tess Levy   +22 more
wiley   +1 more source

Mergers and acquisitions in the insurance sector: A systematic and bibliometric analysis of research trends, determinants, and future directions [PDF]

open access: yesInsurance Markets and Companies
Type of the article: Research Article Abstract Mergers and acquisitions (M&A) are increasingly popular transactions in financial markets, often seen as a faster and safer way to achieve growth and create value. However, research focusing exclusively
Lucileyd Ceita   +2 more
doaj   +1 more source

Guarding against financial distress: The power of institutional ownership in Indonesia’s insurance firms [PDF]

open access: yesInsurance Markets and Companies
Type of the article: Research Article AbstractThis study aims to analyze the influence of financial performance, consisting of solvency, profitability, and liquidity, on financial distress moderated by good corporate governance (institutional ownership).
Hedwigis Esti Riwayati   +3 more
doaj   +1 more source

Examining insurance companies' use of technology for innovation. [PDF]

open access: yesGeneva Pap Risk Insur Issues Pract, 2022
Lanfranchi D, Grassi L.
europepmc   +1 more source

Home - About - Disclaimer - Privacy